- Home
- SKYW vs TNGX Comparison
SKYW vs TNGX Comparison
Compare SKYW & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYW | TNGX |
|---|---|---|
| Founded | 1972 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SKYW | TNGX |
|---|---|---|
| Price | $83.54 | $23.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $123.67 | $21.78 |
| AVG Volume (30 Days) | 352.9K | ★ 2.8M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.20 | 26.89 |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $2,971,963,000.00 | $62,384,000.00 |
| Revenue This Year | $8.35 | N/A |
| Revenue Next Year | $3.55 | N/A |
| P/E Ratio | $32.51 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $80.00 | $1.04 |
| 52 Week High | $123.94 | $28.41 |
Technical Indicators
Market Signals| Indicator | SKYW | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 54.38 |
| Support Level | N/A | $6.83 |
| Resistance Level | $102.83 | $28.41 |
| Average True Range (ATR) | 3.31 | 1.82 |
| MACD | -0.94 | -0.61 |
| Stochastic Oscillator | 16.56 | 39.74 |
Price Performance
Historical ComparisonAbout SKYW SkyWest Inc.
SkyWest Inc offers commercial air services in the United States, Canada, Mexico, and the Caribbean. Additionally, it leases aircraft to capable users to help generate revenue. SkyWest generally provides regional flights and utilizes smaller, lower-cost aircraft to carry passengers who book tickets through partner airlines. It partners with carriers to fly and operate aircraft for a fee and may use the carriers' brands and ground support to coordinate marketing and transport passengers. The company has two reportable segments: SkyWest Airlines and SWC, which generate maximum revenue, and SkyWest Leasing activities.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.